Expertise in

conditions

Dr. Uzair B. Chaudhary

Oncology

University Oncology Associates Inc.

2335 E Kashian Ln Ste 301,

Fresno, CA

Clinical Trials:Currently Recruiting for 2 Trials

Offers Telehealth

Expertise in

conditions

University Oncology Associates Inc.

2335 E Kashian Ln Ste 301,

Fresno, CA

Overview

Uzair Chaudhary is an Oncologist practicing medicine in Fresno, California.

Dr. Chaudhary is highly rated in 60 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, and Familial Pancreatic Cancer.

He is actively involved in clinical research, co-authoring 11 peer reviewed articles and participating in 26 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in CA

Hospital Affiliations

Community Regional Medical Center

Clovis Community Medical Center

Kaweah Health Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Alignment Health Plan

MEDICARE MAPD
MEDICARE SNP
OTHER MEDICARE
OTHER MEDICARE PART D

Anthem BCBS

Blue Cross Blue Shield

Blue Shield of California

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE-MEDICAID PLAN
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Cigna

Commonwealth Care Alliance

MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN

Health Care Services Corporation

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana

HMO
INDEMNITY
POS
PPO

Managed Medicaid

OTHER MANAGED MEDICAID

Medicaid

OTHER MEDICAID
STATE MEDICAID

SCAN Health Plan

INSURANCE PLAN
MEDICARE MAPD

Sentara Healthcare

INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE ASSISTANCE PROGRAM
MEDICARE MAPD
MEDICARE SNP
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D

UnitedHealthcare

Walgreens

MEDICARE DISCOUNT CARD
MEDICARE PDP
OTHER MEDICARE

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 12 Less Insurance Carriers -

Locations

University Oncology Associates Inc.
2335 E Kashian Ln Ste 301, Fresno, CA 93701

Call: 559-256-9680

Other Locations

Community Medical Oncology Specialists
785 N Medical Center Dr W Ste 203, Clovis, CA 93611

Call: 559-387-1900

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

26 Clinical Trials

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

Enrollment Status: Recruiting

Publish Date: September 08, 2026

Intervention Type: Procedure, Biological, Drug

Study Drugs: Cabozantinib, Ipilimumab, Nivolumab

Study Phase: Phase 2

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL

Enrollment Status: Recruiting

Publish Date: September 02, 2026

Intervention Type: Biological, Drug, Procedure, Other

Study Drugs: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab

Study Phase: Phase 3

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial

Enrollment Status: Terminated

Publish Date: September 04, 2026

Intervention Type: Other, Drug

Study Drug: Aspirin

Study Phase: Phase 3

A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

Enrollment Status: Suspended

Publish Date: September 01, 2026

Intervention Type: Biological, Drug, Procedure, Radiation

Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel

Study Phase: Phase 2/Phase 3

A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy